ARTAN-102

ARTAN-102 is a gene therapy developed by ARTAN Bio that uses an engineered **suppressor tRNA system** delivered via **AAV9 viral vectors** to target and suppress **nonsense mutations**, specifically the CGA codon that mutates to an opal-stop codon. These nonsense mutations result in premature termination codons (PTCs) that produce incomplete, nonfunctional proteins and are implicated in approximately 10% of genetic diseases as well as age-related conditions including cancer, neurodegeneration, and Alzheimer's disease. The therapy aims to restore normal protein translation and function by specifically recognizing and suppressing these arginine nonsense mutations without competing with normal tRNA. ARTAN-102 represents the lead candidate from ARTAN Bio's codon suppressor platform and has demonstrated the ability to restore p53 protein production in preclinical studies. In animal studies, ARTAN-102 showed zero adverse effects and successfully reached all six target organs including the brain. The therapy is being developed through a collaboration with Syenex for precision in vivo delivery using the VivoCell Platform, and manufacturing is being conducted in partnership with Lonza. This represents the first tokenized gene therapy, with the intellectual property initially funded by VitaDAO and subsequently tokenized through VitaRNA.

Other names

Vita-mutation-specific codon suppression-genetic medicine-aging-longevitymutation-specific codon suppression genetic medicineVitaRNA